#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2868	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2363	355.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1581	1581	C	415	C,T	338,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4460	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4033	331.2	0	.	n	.	0	T695C	SNP	695	695	T	1271	1271	C	385	C,A,T	337,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4460	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4033	331.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1913	1913	A	335	A,C	286,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4460	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4033	331.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2547	2547	C	389	CCACAC,CCAC	325,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4460	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4033	331.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2621	2621	A	403	A,G	343,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4460	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4033	331.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3173	3173	C	352	C,T	298,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	374	folP	855	855	100.0	folP.l15.c4.ctg.1	2022	55.2	1	SNP	p	R229S	0	.	.	685	687	CGC	1281	1283	CGC	84;84;84	C;G;C	70;69;67	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3927	73.1	1	SNP	p	S91F	0	.	.	271	273	TCC	838	840	TCC	79;78;78	T,G;C;C	66,1;68;68	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3927	73.1	1	SNP	p	D95G	0	.	.	283	285	GAC	850	852	GAC	78;77;76	G;A;C,A	67;64;65,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3927	73.1	1	SNP	p	D95N	0	.	.	283	285	GAC	850	852	GAC	78;77;76	G;A;C,A	67;64;65,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	452	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1681	80.5	1	SNP	p	G45D	1	.	.	133	135	GAC	654	656	GAC	132;132;133	G;A,C;C,A	106;107,1;109,2	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	302	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1301	69.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	852	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3418	74.6	1	SNP	p	D86N	0	.	.	256	258	GAC	843	845	GAC	82;83;83	G;A;C	71;70;71	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	852	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3418	74.6	1	SNP	p	S88P	0	.	.	262	264	TCC	849	851	TCC	85;85;85	T;C;C	73;78;78	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	718	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3128	68.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1743	1745	GGC	100;99;97	G;G;C	76;76;72	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1513	1515	GCA	106;106;107	G;C;A	93;93;94	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1516	1518	ATC	106;106;107	A;T;C	93;87;91	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1528	1530	GTG	108;109;109	G;T,G;G	92;87,1;91	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1528	1530	GTG	108;109;109	G;T,G;G	92;87,1;91	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2032	2034	ACC	45;46;46	A;C;C	34;41;38	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2086	2088	GCG	47;47;47	G;C,G;G	42;34,1;40	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2086	2088	GCG	47;47;47	G;C,G;G	42;34,1;40	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2209	2211	GGC	56;55;56	G;G;C	46;48;47	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2218	2220	GGC	57;58;58	G;G;C	48;52;47	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	652	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2880	67.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2236	2238	CTG	60;60;60	C;T;G	49;50;50	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	926	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3606	76.9	1	SNP	p	L421P	1	L421P	NONSYN	1261	1263	CTG	1922	1924	CCG	78;77;75	C;C;G	67;69;68	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	452	porA	1146	1146	99.83	porA.l6.c17.ctg.1	2266	59.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	610	612	GGC	93;93;93	G;G;C	79;81;82	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	452	porA	1146	1146	99.83	porA.l6.c17.ctg.1	2266	59.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	792	792	C	79	C	64	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	62	porB1a	984	177	90.06	porB1a.l15.c4.ctg.1	1315	13.2	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1163	1165	AAT	6;6;6	A;A;T	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	62	porB1a	984	177	90.06	porB1a.l15.c4.ctg.1	1315	13.2	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1166	1168	AAT	6;6;6	A;A;T	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	62	porB1a	984	177	90.06	porB1a.l15.c4.ctg.1	1315	13.2	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1178	1180	GTT	6;6;6	G;T;T	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	62	porB1a	984	177	90.06	porB1a.l15.c4.ctg.1	1315	13.2	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1190	1192	GCG	7;7;7	G;C;G	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	62	porB1a	984	177	90.06	porB1a.l15.c4.ctg.1	1315	13.2	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1213	1215	GTA	7;7;7	G;T;A	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	62	porB1a	984	177	90.06	porB1a.l15.c4.ctg.1	1315	13.2	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1225	1225	G	7	G	6	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	A29V	NONSYN	85	87	GCC	705	707	GTC	131;131;131	G,T;T;C	104,1;102;107	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	978	980	AAG	113;113;112	A;A;G	101;99;99	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	N124S	NONSYN	370	372	AAT	990	992	AGT	108;108;107	A;G;T	91;94;90	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	1047	1049	CAA	100;100;100	C;A;A	86;86;84	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1254	1256	GAT	90;89;89	G;A;T	81;75;80	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1257	1259	GGT	90;90;89	G;G;T	80;82;78	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1263	1265	GCT	87;87;87	G;C;T	80;76;78	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1272	1274	ATG	85;85;86	A;T;G,A	80;79;78,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1389	1391	ACG	90;89;89	A;C;G,T	76;76;75,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1395	1397	GTT	93;92;93	G,T;T,C;T	78,1;79,1;78	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1509	1511	AAC	88;88;88	A;A;C	75;74;72	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	1	SNP	p	D121N	0	.	.	361	363	GAC	981	983	GAC	113;111;110	G;A;C	98;95;93	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	532	porB1b	1047	1047	98.57	porB1b.l15.c4.ctg.1	2247	69.6	1	SNP	p	A121D	1	.	.	361	363	GAC	981	983	GAC	113;111;110	G;A;C	98;95;93	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1754	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	5153	101.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	316	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1348	70.1	1	SNP	p	V57M	1	.	.	169	171	ATG	718	720	ATG	123;123;123	A;T;G	105;104;104	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
